Interview with Jan Smeitink, CEO of Khondrion
Eight years ago, Jan Smeitink looked at himself in the mirror and decided he is going to change the world. Today, Jan is the Chief Executive Officer of Khondrion and is starting Phase 2b clinical trials for his revolutionary drug, KH176 – which might well become the first treatment on the market for people suffering from the devastating mitochondrial diseases.
We visited Jan, and his colleague Julien Beyrath, Chief Operating Officer, at the headquarters of Khondrion, a high-tech lab in a labyrinth of hallways at the Radboud Medical University in Nijmegen, the Netherlands.
Catalyze and Khondrion started working together more than 7 years ago and this was a celebratory visit, since Khondrion has recently been awarded a €2.3 Million SME Instrument Phase 2 grant. We took this opportunity to talk more about the inspiring mission of Khondrion and their journey.
Subscribe to our newsletter to receive news and resources about funding for life sciences and innovations.